Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans
暂无分享,去创建一个
Mark Muzi | David A. Mankoff | Jashvant D. Unadkat | Jeanne M. Link | D. Mankoff | A. Collier | M. Muzi | L. Sasongko | J. Link | S. Shoner | J. Unadkat | Ann C. Collier | Steve Shoner | Lucy Sasongko
[1] Mark Muzi,et al. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] Mark Lubberink,et al. Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] E. Meyer. Simultaneous correction for tracer arrival delay and dispersion in CBF measurements by the H215O autoradiographic method and dynamic PET. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] G. Barger,et al. In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas , 2006, Clinical Cancer Research.
[5] D. Mankoff,et al. Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.
[6] E. Franssen,et al. In vivo measurement of [11C]verapamil kinetics in human tissues , 2001, European Journal of Clinical Pharmacology.
[7] R. Boellaard,et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. , 2003, Nuclear medicine and biology.
[8] Willem Boogerd,et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? , 2004, Cancer treatment reviews.
[9] M. Lubberink,et al. Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[10] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] I. Pastan,et al. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. , 1990, The Journal of biological chemistry.
[12] Eve M. Taylor,et al. The Impact of Efflux Transporters in the Brain on the Development of Drugs for CNS Disorders , 2002, Clinical pharmacokinetics.
[13] R. Bendayan,et al. Functional Expression and Localization of P-glycoprotein in the Central Nervous System: Relevance to the Pathogenesis and Treatment of Neurological Disorders , 2004, Pharmaceutical Research.
[14] Mark Muzi,et al. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] Yuichi Sugiyama,et al. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] Gert Luurtsema,et al. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. , 2005, Nuclear medicine and biology.
[17] Finbarr O'Sullivan,et al. Imaging radiotracer model parameters in PET: a mixture analysis approach , 1993, IEEE Trans. Medical Imaging.
[18] A. Shervington,et al. Expression of Multidrug Resistance Genes in Normal and Cancer Stem Cells , 2008, Cancer investigation.
[19] Joost Bart,et al. Quantitative assessment of P-glycoprotein function in the rat blood–brain barrier by distribution volume of [11C]verapamil measured with PET , 2003, NeuroImage.
[20] R. Grubb,et al. Regional cerebral blood volume in humans. X-ray fluorescence studies. , 1973, Archives of neurology.
[21] M. Graham,et al. High-speed automated discrete blood sampling for positron emission tomography. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] H Akaike,et al. [Data analysis by statistical models]. , 1992, No to hattatsu = Brain and development.
[23] J Marshall,et al. In vivo Measurement of Regional Cerebral Haematocrit Using Positron Emission Tomography , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[24] D. Mankoff,et al. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] T. Fukami,et al. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood–brain barrier , 2007, Journal of drug targeting.
[26] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.
[27] Thomas K. Lewellen,et al. Investigation of the performance of the General Electric Advance positron emission tomograph in 3D mode , 1995 .
[28] Yuichi Sugiyama,et al. Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] Gary M Pollack,et al. Modulation of P-glycoprotein Transport Activity in the Mouse Blood-Brain Barrier by Rifampin , 2003, Journal of Pharmacology and Experimental Therapeutics.